laronidase: clinical use

Prescribing considerations

• Specialist supervision and immediate access to resuscitation facilities are required.
• Assess current clinical status before infusion; acute illness may increase infusion-reaction risk.
• Use particular caution with severe MPS I-related upper-airway or pulmonary involvement.
• Consider premedication according to previous reactions and clinical circumstances.
• Restarting after a prolonged interruption may carry an increased theoretical hypersensitivity risk.
• Record the product name and batch number for biological-medicine traceability.

Contraindications and cautions

• Severe hypersensitivity, including anaphylaxis, to laronidase or an excipient.

Monitoring

• Observe for infusion-associated, delayed and hypersensitivity reactions, including respiratory status, oxygen saturation and haemodynamic changes.
• Monitor relevant anti-drug antibodies, including neutralising antibodies, as directed by the specialist service.
• If clinical decline occurs, consider urinary glycosaminoglycans and antibody assessment.
• Review infusion suitability and emergency arrangements before any move to home administration.

Clinical pharmacology

Recombinant human alpha-L-iduronidase is taken into cellular lysosomes, probably through mannose-6-phosphate receptors. As a protein, it is expected to undergo peptide hydrolysis; renal elimination is a minor clearance pathway.

Formulation and product differences

• The product is a single-use intravenous concentrate requiring aseptic dilution with sodium chloride solution.
• Use an infusion set with an appropriate in-line filter.
• Unopened vials require refrigerated storage.
• The formulation contains sodium and polysorbate 80.